Hear how Deb faced her ALS diagnosis and worked with her neurologist to start RADICAVA ORS®.
Enroll in the ALS Care Locator
MEDICAL PRACTICERADICAVA ORS® recognized as a MAJOR CONTRIBUTION TO PATIENT CARE by the FDA.1 Request a rep visit.
Hear how Deb faced her ALS diagnosis and worked with her neurologist to start RADICAVA ORS®.
Ken and his wife Andi share their story and discuss their thoughts on ALS and RADICAVA ORS®.
Retired firefighter Ken shares how he moves forward with courage.
Andi discusses her experience with ALS challenges as care partner to Ken.
Kate and care partner Kevin share their ALS and RADICAVA ORS® experience.
Hear how Kate worked with her doctor to switch to RADICAVA ORS® and how she feels about taking this oral treatment for ALS.
Hear how Albert developed a mindset that helped him focus on the moment while living with ALS as well as his treatment experience with RADICAVA ORS® (edaravone).
Linda worked with several doctors before arriving at an ALS diagnosis. Hear her experience with this process and treatment with RADICAVA®.
Like many caregivers, Gia took care of a family member with ALS. Hear her experience with her father and how he was switched from the IV form to RADICAVA ORS® (edaravone).
Hear how Debra and Jennifer's unique patient-caregiver connection helps them move forward with a positive attitude together.
A caregiver's positive administration experience when switching from IV to oral RADICAVA®.
Debra talks about her experience with diagnosis, how her family gives her great support, and how she focuses on moving forward.
Juan and his wife/caregiver Meg discuss the importance of support when facing ALS, as well as their thoughts on RADICAVA® treatment.
Ned talks about his experience with ALS diagnosis, important moments in his life with ALS, and how he embraces his now by focusing on living for today.
Ned talks abut why RADICAVA® matters to him and how he works with his family to fit treatment into his daily routine.
Mara Dolan and her husband, Pat, have been married for 20 years. She explains why it's so important to be your own advocate, how she learned to administer RADICAVA® (edaravone), and what it's like to give Pat his infusions at home.
Juan Reyes is a father of 4 who has been living with ALS since October of 2015. He explains why he chooses to travel to an infusion center to receive his ALS treatments and how he and his caregiver, Angie, pass the time during his infusions with RADICAVA® (edaravone).
Susan talks about taking control of her daily life and what she looks forward to when getting her infusions.
These individuals have received compensation from MTPA for these videos.
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information.
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information.
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America.
This link may take you to a website to which our Privacy Policy does not apply.
Mitsubishi Tanabe Pharma America does not control the content of third-party sites.